Skip to content
10-Q

Quarterly Report

RIGEL PHARMACEUTICALS INC RIGL

0001558370-25-006493

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 17.87M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $60M
Short Term Investments Q1 2025 · Mar 31, 2025 $31.37M
Short Term Investments Q1 2025 · Dec 31, 2024 $20.58M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $45.73M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $56.75M
Current Liabilities Q1 2025 · Mar 31, 2025 $66.63M
Current Liabilities Q1 2025 · Dec 31, 2024 $63.3M
Total Liabilities Q1 2025 · Mar 31, 2025 $157.41M
Total Liabilities Q1 2025 · Dec 31, 2024 $160.69M
Current Assets Q1 2025 · Mar 31, 2025 $146.56M
Current Assets Q1 2025 · Dec 31, 2024 $135.1M
Total Assets Q1 2025 · Mar 31, 2025 $175.97M
Total Assets Q1 2025 · Dec 31, 2024 $163.98M
Shares Diluted restated Q1 2025 · Mar 31, 2024 17.52M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$5.01M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$31.67M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$28.64M
Eps Diluted restated Q1 2025 · Mar 31, 2024 −$0.47
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.47
Sga Expense Q1 2025 · Mar 31, 2024 $28.45M
Net Income Q1 2025 · Mar 31, 2024 −$8.25M
Operating Income Q1 2025 · Mar 31, 2024 −$6.97M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $2.03M
Revenue Q1 2025 · Mar 31, 2024 $29.53M